Trial Profile
Prospective, Non-interventional Observation Study for the Use of Palivizumab in High-risk Children in Germany- SYNAGIS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 16 Jul 2018 Results from the German Synagis Registry 2009-2016 published in the Pediatric Infectious Disease Journal.
- 15 Aug 2016 Status changed from recruiting to completed.
- 19 May 2014 Planned end date changed from 1 May 2015 to 1 May 2017 as reported by ClinicalTrials.gov.